immune response

The experimental drug NP001 slowed or halted disease progression in some trial participants with ALS; a phase 3 trial is planned for 2013

Posted on Monday, November 5, 2012 - 05:00, By: Amy Madsen
Update (Dec. 12, 2013): In a Dec. 9, 2013, press release, Neuraltus reported that NP001 treatment in the phase 2 trial showed positive trends in slowing ALS progression and that the data support the hypothesis that NP001's primary mechanism of action is restoration of normal function of...
Posted on Saturday, May 1, 2010 - 11:43, By: ALSN Staff
IMMUNE SYSTEM MODULATOR HERALDS NEW STRATEGY IN ALS RESEARCH Blocking a key molecular pathway that the body uses to amplify an immune response has been found to delay disease onset and extend survival in mice with a disease that mimics human ALS, say researchers at the MDA-supported ALS Therapy...

ALS TDI investigators have found that disrupting part of the immune system slows disease progression in mice with an ALS-like disease

Posted on Monday, March 29, 2010 - 14:04, By: Margaret Wahl
Blocking a key molecular pathway that the body uses to amplify an immune response has been found to delay disease onset and extend survival in mice with a disease that mimics human amyotrophic lateral sclerosis (ALS), say researchers at the MDA-supported ALS Therapy Development Institute (ALS...

Advertisements

myMuscleTeam